Gavestinel Sodium

• CAT Number: I006935
• CAS Number: 153436-38-5 (Gavestinel Sodium)
• Molecular Formula: C18H11Cl2N2NaO3
• Molecular Weight: 397.18
• Purity: ≥95%
• Synonyms: GV-150526A; GV150526A; GV 150526A;sodium (E)-4,6-dichloro-3-(3-oxo-3-(phenylamino)prop-1-en-1-yl)-1H-indole-2-carboxylate
• Target: Neuronal Signaling
• Solubility: Soluble in DMSO
• Storage: 0 - 4°C for short term or -20 °C for long term
• IUPAC Name: sodium;3-[(E)-3-anilino-3-oxoprop-1-enyl]-4,6-dichloro-1H-indole-2-carboxylate
• InChI: InChI=1S/C18H12Cl2N2O3.Na/c19-10-8-13(20)16-12(17(18(24)25)22-14(16)9-10)6-7-15(23)21-11-4-2-1-3-5-11;/h1-9,22H,(H,21,23)(H,24,25);/q;+1/p-1/b7-6+
• InChIKey: GRSDSTMFQHAESM-UHDJGPCESA-M
• SMILES: O=C(C(N1)=C(/C=C/C(NC2=CC=CC=C2)=O)C3=C1C=C(Cl)C=C3Cl)[O-].[Na+]

Gavestinel Sodium(CAT: I006935) is a potent and selective antagonist of the glycine-binding site on the NMDA receptor, widely studied for its neuroprotective properties. It inhibits NMDA receptor overactivation, which is implicated in excitotoxicity and neuronal damage in conditions such as stroke, traumatic brain injury, and neurodegenerative disorders. Gavestinel Sodium is valuable for research exploring mechanisms of glutamatergic signaling, synaptic plasticity, and neuroprotection. Its high specificity and efficacy make it a critical tool in preclinical studies aiming to develop therapeutic strategies for central nervous system disorders.